DJIA 18,132.70 -81.72 -0.45%
NASDAQ 4,963.53 -24.36 -0.49%
S&P 500 2,104.50 -6.24 -0.30%
market minute promo

Vertex Pharmaceuticals (NASDAQ: VRTX)

119.43 -0.54 (-0.45%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

VRTX $119.43 -0.45%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $119.92
Previous Close $119.97
Daily Range $118.21 - $120.52
52-Week Range $59.79 - $127.69
Market Cap $28.9B
P/E Ratio -38.21
Dividend (Yield) $0.00 (0.0%)
Volume 1,050,126
Average Daily Volume 1,541,642
Current FY EPS -$1.93

Sector

Healthcare

Industry

Drug Makers

Vertex Pharmaceuticals (VRTX) Description

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Website: http://www.vrtx.com/

News & Commentary Rss Feed

Surprise! We Still Need Drugmakers to Develop Revolutionary Hepatitis C Drugs

Gilead Sciences' and AbbVie's hepatitis C drugs work better than prior-generation treatments, but more work remains.

Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst B

Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog

Short Sellers Come Back To Biotech Stocks

PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer

What to Expect From Vertex Pharma's Next Cystic Fibrosis Drug Results

Upcoming FDA Decisions We're Most Excited About

Three Motley Fool experts tell readers what upcoming FDA decisions have caught their eye.

Could This Be The Biggest Advance in Hepatitis C since Gilead Sciences' Sovaldi?

Achillion Pharmaceuticals is developing a short duration hepatitis C drug that could revolutionize treatment.

In Case You Missed It, There's a New Fastest Growing Drug in the World

For the third time in four years we have a new fastest growing drug of all-time. Find out what drug unseated previous champion Sovaldi for the top honor.

2 Small Biotech Stocks Dreaming Big in Hepatitis C

Exciting but speculative -- Industry Focus examines two companies making strides in the treatment of hepatitis C.

Short Sellers Retreat From Biotech Stocks

See More VRTX News...

VRTX's Top Competitors

VRTX $119.43 (-0.45%)
Current stock: VRTX
AMGN $157.72 (-0.79%)
Current stock: AMGN
GILD $103.53 (-0.63%)
Current stock: GILD
BIIB $409.59 (-0.12%)
Current stock: BIIB